HC Wainwright Forecasts Strong Price Appreciation for MediWound (NASDAQ:MDWD) Stock

MediWound (NASDAQ:MDWD) had its price objective increased by analysts at HC Wainwright from $25.00 to $31.00 in a report released on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 55.86% from the company’s previous close.

A number of other equities analysts also recently weighed in on MDWD. Alliance Global Partners assumed coverage on shares of MediWound in a research note on Friday, May 2nd. They set a “buy” rating and a $25.00 target price for the company. Craig Hallum started coverage on MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 price target for the company. Finally, StockNews.com raised MediWound to a “sell” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, MediWound has an average rating of “Moderate Buy” and a consensus target price of $31.25.

MediWound Price Performance

Shares of MDWD opened at $19.89 on Thursday. The business has a 50-day moving average of $17.41 and a 200-day moving average of $17.59. The company has a market capitalization of $214.97 million, a price-to-earnings ratio of -6.86 and a beta of 0.30. MediWound has a 1 year low of $12.78 and a 1 year high of $24.00.

MediWound (NASDAQ:MDWD) last released its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to the consensus estimate of $5.20 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same quarter in the prior year, the firm posted ($1.05) EPS. As a group, sell-side analysts anticipate that MediWound will post -2.66 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of MDWD. Rhumbline Advisers grew its holdings in MediWound by 7.3% in the fourth quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 739 shares during the period. Barclays PLC boosted its position in shares of MediWound by 11.2% during the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock worth $221,000 after purchasing an additional 1,249 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,162 shares during the period. Geode Capital Management LLC grew its stake in shares of MediWound by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company’s stock valued at $1,757,000 after buying an additional 3,408 shares during the period. Finally, Essex Investment Management Co. LLC increased its position in MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock valued at $2,651,000 after buying an additional 35,012 shares in the last quarter. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.